Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
NCT Number: NCT00165295
The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Boston, Massachusetts, 02115, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dana-Farber Cancer Institute
Other
Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04274738
Blood Protein Disorders, Cardiovascular Diseases
Denver, Colorado, United States
View Trial DetailsNCT02604511
Blood Protein Disorders, Cardiovascular Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT01647971
B-cell Lymphoma, Blood Protein Disorders
Huntsville, Alabama, United States
View Trial DetailsNCT01046006
Blood Protein Disorders, Cardiovascular Diseases
Athens, Attica, Greece
View Trial Details